Biotech RadarJobs updated

COMPANY

Prothena

HQ: Brisbane, CA source · prothena.com ↗

Clinical Phase 3

Keywords: neurology AL Amyloidosis Psoriasis Parkinson's Disease Light Chain (AL) Amyloidosis Primary Systemic (AL) Amyloidosis Amyloidogenic Transthyretin (ATTR) Amyloidosis Amyloidosis Primary Amyloidosis NEOD001 PRX003 PRX002 PRX019 PRX004

Location: Brisbane, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

13Trials (company is sponsor)

Timeline

  1. Trial start 1: Phase 1 Study of PRX019 in Healthy Adult Volunteers source ↗
  2. Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis source ↗
  3. Trial start Phase 1: A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis source ↗
  4. Trial start Phase 2: Study in Subjects With Light Chain (AL) Amyloidosis source ↗
  5. Trial start Phase 1: Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis source ↗
  6. Trial start 2: The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis source ↗
  7. Trial start Phase 2: Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis source ↗
  8. Trial start —: Quality of Life (QOL) Registry for Patients With AL Amyloidosis source ↗
  9. Trial start Phase 1: Single Ascending Dose Study of PRX003 in Healthy Subjects source ↗
  10. Trial start 3: The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis source ↗
  11. Trial start Phase 1: Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease source ↗
  12. Trial start Phase 1: Single Ascending Dose Study of PRX002 in Healthy Subjects source ↗
  13. Trial start 1: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis source ↗

Clinical trials (lead sponsor) 13

RecordTitlePhaseStatusStartPrimary completion
NCT06699680Phase 1 Study of PRX019 in Healthy Adult Volunteers1CompletedNov 8, 2024Jan 16, 2026 (actual)
NCT04973137A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL AmyloidosisPhase 3TerminatedAug 30, 2021Apr 2, 2025 (actual)
NCT02312206The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis3Terminated2015-022018-05 (actual)
NCT03336580A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) AmyloidosisPhase 1TerminatedApr 5, 2018Jul 23, 2020 (actual)
NCT02613182Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) AmyloidosisPhase 2Terminated2016-022018-05 (actual)
NCT02574676Quality of Life (QOL) Registry for Patients With AL AmyloidosisNot listedCompleted2015-102018-07 (actual)
NCT02632786The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis2Completed2016-032018-03 (actual)
NCT03154047Study in Subjects With Light Chain (AL) AmyloidosisPhase 2TerminatedJun 14, 2017May 30, 2018 (actual)
NCT01707264Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis1Completed2013-04Aug 9, 2016 (actual)
NCT02630901Multiple Ascending Dose Study of PRX003 in Subjects With PsoriasisPhase 1CompletedMar 17, 2016Feb 28, 2018 (actual)
NCT02157714Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's DiseasePhase 1Completed2014-062016-09 (actual)
NCT02458677Single Ascending Dose Study of PRX003 in Healthy SubjectsPhase 1Completed2015-052016-02 (actual)
NCT02095171Single Ascending Dose Study of PRX002 in Healthy SubjectsPhase 1Completed2014-032014-12 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback